Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising
cerevisiae ) did not work well
Zofran: headache, constipation, dizziness, rare QT prolongation
American Journal of Health Promotion
A deepening yellow color over time often indicates oxidation
I just didn't say it, but every time somebody squeezed me, dude, I thought I was gonna cry." Thankfully, he was able to get back onto the proverbial saddle